Market Place
Sourcing Support
Azurity scores FDA nod for new formulation of Novartis` Tasigna
16 Nov 2024 //
FIERCE PHARMA
Azurity Pharma Announces FDA Approval of Danziten Tablets
14 Nov 2024 //
PR NEWSWIRE
MSN`s Generics Nilotinib Receives Tentative Approval in US
02 Oct 2024 //
FDA
Xspray`s XS003 Shows Matching Bioavailability At Lower Dose
09 Jul 2024 //
BUSINESSWIRE
Novartis Scemblix ph III data first to show superior efficacy tolerability
03 Jun 2024 //
PHARMABIZ
Apotex`s Generic Nilotinib Hydrochloride Receives Approval in the U.S.
05 Jan 2024 //
FDA
Eugia signs voluntary license with Medicines Patent Pool to develop Nilotinib
23 Jun 2023 //
INDIANPHARMAPOST
Aurobindo arm signs pact with Medicines Patent Pool to develop anti-cancer drug
23 Jun 2023 //
ECONOMIC TIMES
Novartis will let generic Tasigna to be provided to poor nations
23 Jun 2023 //
FIERCE PHARMA
MPP signs on four generics makers to make Novartis` Tasigna more accessible
22 Jun 2023 //
ENDPTS
Novartis Pharma Signs World`s 1st Licensing Deal For Cancer Drug
21 Oct 2022 //
NDTV
Novartis signs landmark licensing deal to expand access to patented cancer drug
20 Oct 2022 //
ENDPTS
Novartis Blocks Sun’s Nilotinib Plans In India
29 Sep 2020 //
INFORMA
Leukaemia drug nilotinib shows promise against Alzheimer’s clinical study
29 May 2020 //
PHARMAFILE
Evidence of a link between Parkinson`s disease & gut could inspire treatments
27 Jun 2019 //
FIERCE BIOTECH
Repurposing Novartis’ cancer drug Tasigna in Parkinson’s
14 Mar 2019 //
FIERCE BIOTECH
Defying Trump, drugmakers hike prescription drug prices for 2019
02 Jan 2019 //
NBC NEWS
Novartis, Pfizer, AZ and more hand China 50%-plus cancer drug discounts
11 Oct 2018 //
FIERCE PHARMA
EMA Assessmt & Procedural Steps for Incyte`s Iclusig (ponatinib)
10 Oct 2018 //
EMA
EMA Assessment of Incyte Biosciences` Iclusig (ponatinib) & Procedural steps
10 Oct 2018 //
EMA
Enforcement Report - Week of May 16, 2018
16 May 2018 //
FDA
Lawsuits Allege Safety Concern Over Novartis CML Drug Tasigna
29 Mar 2018 //
BIOSPACE
Tasigna cleared for use in children with rare leukemia
24 Mar 2018 //
PHARMA TIMES
Novartis drug Tasigna® approved by FDA to treat children with rare leukemia
22 Mar 2018 //
PR NEWSWIRE
FDA’s year-end approvals take annual tally to 46
02 Jan 2018 //
PMLIVE
Novartis drug tasigna is approved by FDA as first and only CML therapy
27 Dec 2017 //
PHARMABIZ
EU approves Novartis drug Tasigna 1st & IInd-line treatment of Ph+ CML-CP child
20 Nov 2017 //
PHARMABIZ
CML patients in England win access to Incyte’s Iclusig
03 May 2017 //
FIERCE BIOTECH
Novartis Announces New Data From Tasigna ENESTop TFR
05 Dec 2016 //
NASDAQ
Under drug-cost attack, Big Pharma CEOs raise the value-based pricing flag
07 Nov 2016 //
FIERCE PHARMA
Novartis cancer drug to be tested for Parkinson’s disease
14 Jul 2016 //
FIERCE BIOTECH
BCR-ABL Tyrosine Kinase Inhibitors - Risk of Hepatitis B Reactivation
06 May 2016 //
HEALTH CANADA
Health Canada Require Updated Warning on Gleevec Labeling for Brand and Generics
05 May 2016 //
TWOFOUR INSIGHT
BCR-ABL Tyrosine Kinase Inhibitors
04 May 2016 //
HEALTH CANADA
New Novartis meds help relieve Gleevec generics pain
21 Apr 2016 //
FIERCE PHARMA
Do rebates really take a big chunk out of rising drug prices?
21 Mar 2016 //
FIERCE PHARMA
Novartis braces for multibillion-dollar generics hit as Gleevec copies launch
01 Feb 2016 //
FIERCE PHARMA
Novartis Still Hungry After Absorbing GSK Oncology
25 Apr 2015 //
PMLIVE
GSK Deal`s Done. Now, Novartis Has To Deliver On Cancer-Growth Pledge
03 Mar 2015 //
FIERCE PHARMA
Novartis Faces Suspension in Japan After Series of Trial Data Scandals
03 Feb 2015 //
FIERCE PHARMA
